UnitedHealth vs. Johnson & Johnson: Which Healthcare Stock Wins After Q3?

UnitedHealth Group (UNH) reported third-quarter earnings that blew past analyst expectations, with earnings per share coming in 14% above consensus estimates. The company also delivered impressive 60% year-over-year EPS growth, driven by improved medical cost ratios and operational efficiency. Management raised full-year guidance above Wall Street's expectations, signaling confidence in continued momentum.

Johnson & Johnson (JNJ) reported more modest results. While the company beat earnings estimates by 2%, its earnings declined 7.5% year-over-year. The pharmaceutical division performed well, but weakness in the MedTech segment dragged on overall results. JNJ also raised its full-year guidance, but the increase was slightly below what analysts had anticipated.

From a valuation perspective, UNH trades at a lower multiple than JNJ, making it more attractive on a relative basis. Additionally, UNH offers a higher dividend yield, appealing to income-focused investors. Analyst sentiment also favors UNH: it holds a Zacks Rank #2 (Buy) with positive earnings estimate revisions, while JNJ carries a Zacks Rank #4 (Sell) due to declining earnings estimates.

Both companies operate in the healthcare sector, but their business mixes differ. UNH is a managed care giant, benefiting from stable insurance premiums and growing government programs. JNJ is a diversified healthcare leader with pharmaceuticals, medical devices, and consumer health products. The Q3 results highlight UNH's operational strength versus JNJ's uneven performance.

For investors, UNH's strong Q3 results reinforce its position as a reliable growth and income play in healthcare. The raised guidance suggests that the company's cost management and pricing power are working, which could lead to further earnings surprises. A lower valuation multiple means the stock may still be undervalued relative to its growth prospects, offering potential upside.

JNJ's mixed results raise questions about its near-term growth trajectory. The MedTech weakness is concerning, especially as the company faces competition and pricing pressure. While JNJ's pharmaceutical pipeline remains robust, the earnings decline and premium valuation make it less appealing compared to UNH. The Zacks Rank #4 (Sell) indicates that analysts are revising estimates downward, which often precedes underperformance.

From a sector perspective, healthcare remains a defensive play amid economic uncertainty. However, not all healthcare stocks are created equal. UNH's ability to beat and raise while improving margins demonstrates resilience. JNJ's challenges suggest that diversification isn't always a strength when one segment lags.

For income investors, UNH's higher dividend yield is a clear advantage. For growth investors, UNH's 60% EPS growth is far more attractive than JNJ's decline. Overall, the Q3 earnings season has made a strong case for UNH over JNJ in the near term.